Stock Events

Stock Events

KalVista Pharmaceuticals 

€23.36
0
+€0.00+0% Friday 15:30

Statistics

Day High
23.27
Day Low
23.27
52W High
23.36
52W Low
23.27
Volume
255
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

14MayExpected
Q1 2026
-0.32
0.01
0.35
0.68
Expected EPS
-0.31934425
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 4XC1.XETRA. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alnylam Pharmaceuticals
ALNY
Mkt Cap40.32B
Alnylam Pharmaceuticals specializes in RNAi therapeutics for genetically defined diseases, competing in the same rare disease space as KalVista.
Vertex Pharmaceuticals
VRTX
Mkt Cap113.59B
Vertex Pharmaceuticals engages in creating small molecule drugs for serious diseases, directly competing with KalVista's approach in drug development.
Regeneron Pharmaceuticals
REGN
Mkt Cap64.45B
Regeneron Pharmaceuticals is involved in developing and commercializing medicines for serious diseases, including therapies that could compete with KalVista's portfolio.
Biogen
BIIB
Mkt Cap28.94B
Biogen focuses on discovering, developing, and delivering therapies for neurological diseases, competing for similar patient populations as KalVista.
AMGEN
AMGN
Mkt Cap181.77B
Amgen develops therapeutics in areas including cardiovascular disease, competing with KalVista's efforts in hereditary angioedema.
Novartis
NVS
Mkt Cap286.54B
Novartis offers a broad range of healthcare products including innovative medicines, directly competing across multiple areas including treatments for diseases targeted by KalVista.
Gilead Sciences
GILD
Mkt Cap166.9B
Gilead Sciences focuses on antiviral drugs for infectious diseases, but its expansion into other therapeutic areas could position it as a competitor to KalVista.
Abbvie
ABBV
Mkt Cap384.67B
AbbVie works on a broad portfolio of drugs, including efforts in immunology and oncology, areas that could intersect with KalVista's therapeutic targets.

About

KalVista Pharmaceuticals, Inc., a biopharmaceutical company, develops oral therapies for individuals for rare diseases with unmet needs. Its lead product candidate is EKTERLY, a fast-acting potent inhibitor of plasma kallikrein for the treatment of acute attacks of hereditary angioedema (HAE). The company is also developing is developing an orally disintegrating tablet formulation; KONFIDENT-KID for pediatric use with HAE; KONFIDENT; and KONFIDENT-S to evaluate sebetralstat and ODT formulation in adolescent and adult patients. KalVista Pharmaceuticals, Inc. is headquartered in Framingham, Massachusetts.
Show more...
CEO
Mr. Benjamin L. Palleiko
Employees
275
Country
United States
ISIN
US4834971032
WKN
000A2DG49

Listings

MU
DE
4XC1.MU
STU
DE
4XC1.STU
XETRA
DE
4XC1.XETRA
F
DE
4XC1.F

0 Comments

Share your thoughts

FAQ

What is KalVista Pharmaceuticals stock price today?▼
The current price of 4XC1.XETRA is €23.36 EUR — it has increased by +0% in the past 24 hours. Watch KalVista Pharmaceuticals stock price performance more closely on the chart.
What is KalVista Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange KalVista Pharmaceuticals stocks are traded under the ticker 4XC1.XETRA.
When is the next KalVista Pharmaceuticals earnings date?▼
KalVista Pharmaceuticals is going to release the next earnings report on December 03, 2026.
How many employees does KalVista Pharmaceuticals have?▼
As of June 06, 2026, the company has 275 employees.
In which sector is KalVista Pharmaceuticals located?▼
KalVista Pharmaceuticals operates in the Health & Wellness sector.
When did KalVista Pharmaceuticals complete a stock split?▼
KalVista Pharmaceuticals has not had any recent stock splits.
Where is KalVista Pharmaceuticals headquartered?▼
KalVista Pharmaceuticals is headquartered in Framingham, United States.